These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 25098804)

  • 1. Tumor lysis syndrome: risk factors, diagnosis, and management.
    Burns RA; Topoz I; Reynolds SL
    Pediatr Emerg Care; 2014 Aug; 30(8):571-6; quiz 577-9. PubMed ID: 25098804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to prevent and manage tumor lysis syndrome.
    Held-Warmkessel J
    Nursing; 2010 Feb; 40(2):26-31; quiz 31-2. PubMed ID: 20083976
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting tumor lysis syndrome: new therapeutic options.
    Shonkwiler E
    ONS News; 2006; 21(8 Suppl):49-50. PubMed ID: 16925150
    [No Abstract]   [Full Text] [Related]  

  • 4. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
    Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor lysis syndrome: a systematic review of case series and case reports.
    Firwana BM; Hasan R; Hasan N; Alahdab F; Alnahhas I; Hasan S; Varon J
    Postgrad Med; 2012 Mar; 124(2):92-101. PubMed ID: 22437219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor lysis syndrome.
    Vachani C
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl Nurse Ed):27-8. PubMed ID: 17474360
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of pediatric tumor lysis syndrome.
    Tazi I; Nafl H; Elhoudzi J; Mahmal L; Harif M
    Arab J Nephrol Transplant; 2011 Sep; 4(3):147-54. PubMed ID: 22026339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the management of malignancy-associated hyperuricaemia.
    Mahmoud HH; Leverger G; Patte C; Harvey E; Lascombes F
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):18-20. PubMed ID: 9647616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2010 Jun; (6):CD006945. PubMed ID: 20556770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Lysis Syndrome.
    Barbar T; Jaffer Sathick I
    Adv Chronic Kidney Dis; 2021 Sep; 28(5):438-446.e1. PubMed ID: 35190110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: Analysis from a resource-limited setting.
    Gopakumar KG; Seetharam S; Km JK; Nair M; Rajeswari B; Cs G; Vr P; Thankamony P
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27401. PubMed ID: 30101454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
    Spina M; Nagy Z; Ribera JM; Federico M; Aurer I; Jordan K; Borsaru G; Pristupa AS; Bosi A; Grosicki S; Glushko NL; Ristic D; Jakucs J; Montesinos P; Mayer J; Rego EM; Baldini S; Scartoni S; Capriati A; Maggi CA; Simonelli C;
    Ann Oncol; 2015 Oct; 26(10):2155-61. PubMed ID: 26216382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour lysis syndrome.
    Calvo Villas JM
    Med Clin (Barc); 2019 May; 152(10):397-404. PubMed ID: 30612747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN; Shanholtz CB; Thompson JL
    Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome.
    Davidson MB; Thakkar S; Hix JK; Bhandarkar ND; Wong A; Schreiber MJ
    Am J Med; 2004 Apr; 116(8):546-54. PubMed ID: 15063817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
    McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
    Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor lysis syndrome in intensive therapy: diagnostic and therapeutic encare].
    Burghi G; Berrutti D; Manzanares W
    Med Intensiva; 2011 Apr; 35(3):170-8. PubMed ID: 21112673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
    Wössmann W; Schrappe M; Meyer U; Zimmermann M; Reiter A
    Ann Hematol; 2003 Mar; 82(3):160-5. PubMed ID: 12634948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.